Keeping Up To Date On CRISPR – July 2016

29 July 2016 PharmaPatents Blog
Author(s): Tianran Yan Stephen B. Maebius

CRISPR is a gene editing technique that promises to revolutionize genetic engineering, but already is raising ethical, business, and legal issues. This is the first in a monthly series of articles on CRISPR. If you are interested in more information, please download a digital copy of our web conference on “Navigating the CRISPR Patent Landscape and Business Impact” or contact any of the authors.


The acronym CRISPR stands for clustered regularly interspaced short palindromic repeats, which refers to a pattern of DNA sequences observed in a wide range of bacteria and archaea, where a repeated sequence is interspersed with shorter sequences that correspond to viral DNA sequences. The CRISPR pattern is believed to be associated with a prokaryotic immune defense mechanism that helps the bacteria (or archaea) recognize and attack viral DNA. As part of this immune defense mechanism, these prokaryotes also have genes that encode CRISPR-associated proteins (Cas), that precisely cut target viral DNA sequences and prevent invading viruses from replicating.

The CRISPR system is being applied to genetic engineering by using a Cas protein, such as the Cas9 nuclease from Streptococcus pyogenes, in association with one or more guide RNAs which tell Cas9 precisely where to snip a target DNA sequence. As discussed in Cong et al., Science 339:819-823 (2013), and Mali et al., Science 339:823-826 (2013), this methodology can be used in eukaryotic cells to edit a eukaryotic genome, including a human genome. Because of the excellent editing efficiency and ease of use, CRISPR has been widely hailed as one of the most important biotech discoveries of the 21st century.

CRISPR Clinical Trials

Many groups around the world are actively seeking to harness the power of CRISPR for therapeutic applications. It has been reported that the first human CRISPR clinical trial will soon start in China, in which the CRISPR system will be used to edit T cells of lung cancer patients ex vivo. It also has been reported that a human CRISPR clinical trial has received approval to proceed in the U.S.

U.S. CRISPR Patents and Published Patent Applications in the U.S.

We searched the USPTO database for U.S. patents and published applications that recite “CRISPR” or “Cas9” in either the claims or the abstract. Our search identified 35 CRISPR-related granted U.S. patents and 305 CRISPR-related U.S. patent applications that had been published as of July 27, 2016. (The search results are available here.) This figure highlights the exponential increase in CRISPR-related U.S. patent filings.


Applicants/Assignees who appear to be actively filing in this area include, on the university side, Harvard, MIT, the Broad Institute, and the University of California (Table 1), and on the corporate side, Sangamo, Caribou, Regeneron, Dow, and Agilent (Table 2). Some of the inventors include Feng Zhang of the Broad Institute, David Liu and George Church of Harvard, and Jennifer Doudna of the University of California (Table 3).

Table 1 – Selected University Applicants

Table 2 – Selected Corporate Applicants

Table 3 – Selected Inventors

CRISPR Legislative News

Earlier in July 2106, the Senate passed legislation (S.764) that would require the Secretary of Agriculture to establish a national standard for disclosing “bioengineered” foods that could have implications for CRISPR.

Ongoing CRISPR Updates 

As noted above, this is the first in a monthly series of articles on CRISPR. Make sure you have subscribed to PharmaPatentsBlog (see the Subscribe to This Blog box near the top right of this page) to stay on top of developments in this era-defining technology.

This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.

Related Services


Ten Minute Interview: M&A Challenges & Opportunities
23 November 2022
Sujata “Sue” Sachdeva and Koss Corp.
23 November 2022
Cannabis Company Cops to SEC Accounting Fraud Charges
22 November 2022
Legal News: Cannabis Industry
Foley Automotive Report
22 November 2022
Dashboard Insights
CLE Weeks
5-16 December 2022
Milwaukee, WI
Foley Sponsors Ernst & Young Entrepreneur of the Year® Program
1 December 2021 - 30 November 2022
Michigan and Northwest Ohio Region
2022 Distressed Investing Conference
28 November 2022
New York, NY
Meet and Greet and Panel Discussion with E. Martin Estrada and Cuauhtemoc Ortega
28 November 2022
Los Angeles, CA